| NCT ID | NCT05537298 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kirby Mayer |
| Condition | ICU Acquired Weakness |
| Study Type | OBSERVATIONAL |
| Enrollment | 209 participants |
| Start Date | 2022-10-18 |
| Primary Completion | 2027-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 209 participants in total. It began in 2022-10-18 with a primary completion date of 2027-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness: 1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments 2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors 3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission
Eligibility Criteria
Inclusion Criteria: * adult (\>18 y/o) * admission for sepsis or acute respiratory failure with at least 72 hour stay in ICU Exclusion Criteria: * acute or chronic neurologic condition * acute or chronic orthopedic condition preventing strength/functional testing * patients who were not ambulatory prior to ICU admission * patients not expected to survive \~6months after admission
Contact & Investigator
Kirby P Mayer, PhD
STUDY DIRECTOR
University of Kentucky
Frequently Asked Questions
Who can join the NCT05537298 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying ICU Acquired Weakness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05537298 currently recruiting?
Yes, NCT05537298 is actively recruiting participants. Contact the research team at kpmaye2@uky.edu for enrollment information.
Where is the NCT05537298 trial being conducted?
This trial is being conducted at Birmingham, United States, Lexington, United States, Oklahoma City, United States.
Who is sponsoring the NCT05537298 clinical trial?
NCT05537298 is sponsored by Kirby Mayer. The principal investigator is Kirby P Mayer, PhD at University of Kentucky. The trial plans to enroll 209 participants.